Updated:
DiaMedica Therapeutics
DiaMedica Therapeutics is a clinical-stage biotech betting its valuation on DM199, a single recombinant protein for acute ischemic stroke recovery.
DiaMedica Therapeutics
DiaMedica Therapeutics was founded in Canada in 2000 and now bases its operations from Minneapolis, Minnesota under the leadership of President and CEO Rick Pauls. The company reversed into its current form through a series of early 2010s reorganizations, shedding a diabetes-focused diagnostic legacy to concentrate on recombinant human tissue kallikrein-1 (rhKLK1). The firm's entire platform theory rests on activating the body's intrinsic KLK1-bradykinin system to improve blood flow and reduce inflammation. The firm's clinical strategy zeroes in on DM199 for acute ischemic stroke, a $10B-plus market with only one approved thrombolytic drug class that the vast majority of patients cannot access due to narrow time windows. DiaMedica targets a post-stroke neuroprotection and recovery window of up to 24 hours. A Phase 2 trial showed signals of reduced death and recurrent stroke, leading the FDA to authorize the pivotal ReMEDy2 Phase 2/3 trial in the US. The company also maintains a second indication for DM199 in preeclampsia, under investigator-sponsored studies in South Africa and other geographies. The balance sheet deployment is binary, with cash runway extended specifically to meet the ReMEDy2 data milestone expected in 2026. DiaMedica has no marketed products and a team scaled to a single-asset trial operation, with reported headcount typically below 20. The C-suite includes CFO Scott Kellen. Nasdaq-listed under ticker DMAC, the firm holds no adjacent vehicles or philanthropic arms. In September 2024, the company completed an underwritten public offering generating gross proceeds of approximately $12.7 million, earmarked to fund Phase 3 clinical development and manufacturing. The structural differentiator is radical asset concentration in a class of therapeutics with latent potential but no modern commercial presence. By isolating around KLK1 activation, DiaMedica avoids both the generalist small-molecule competition and the large-platform cell-therapy cost structures that burden peer neurology investments. The entire corporate thesis succeeds or fails on a single regulatory outcome, making it among the purest binary-event exposures available in public biotech.
General information
Firm type
Asset Manager
Year founded
2000
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Minneapolis
Corporate office
Minneapolis, MN, United States
Principals
Rick Pauls
President and CEO
Scott Kellen
Chief Financial Officer
Sector focus
Frequently asked questions
What is DiaMedica Therapeutics' lead drug candidate and its mechanism?
DiaMedica's lead candidate is DM199, a recombinant human tissue kallikrein-1 (rhKLK1) protein. It is designed to supplement the body's natural KLK1-bradykinin pathway, which plays a role in regulating blood flow, inflammation, and oxidative stress. The firm is testing it primarily for acute ischemic stroke, aiming to offer a treatment option for patients who present outside the standard-of-care thrombolytic window.
What clinical trial is critical to DiaMedica's valuation?
The ReMEDy2 trial is a pivotal Phase 2/3 study evaluating DM199 in patients with acute ischemic stroke. The trial is designed based on positive signals from a prior Phase 2 study that showed reductions in death and recurrent stroke. A successful ReMEDy2 readout, expected around 2026, would be the foundation for seeking regulatory approval in the United States.
Does DiaMedica Therapeutics have any other pipeline programs?
Beyond stroke, DiaMedica is investigating DM199 for preeclampsia, a serious hypertensive disorder in pregnancy. This program is currently in earlier-stage, investigator-sponsored clinical studies conducted primarily in South Africa. The company's near-term resources and strategic attention are overwhelmingly concentrated on the ReMEDy2 stroke trial.
How does DiaMedica fund its operations?
As a clinical-stage company with no product revenue, DiaMedica funds operations entirely through equity financings from public capital markets. The firm completed a $12.7 million public offering in September 2024. Management calibrates spending to maintain cash runway through key trial milestones, most critically the ReMEDy2 Phase 2/3 data readout expected in 2026.
On what stock exchange does DiaMedica trade and under what ticker?
DiaMedica Therapeutics is listed on the Nasdaq Capital Market under the ticker DMAC. As a micro-cap biotech with a binary-event profile, its public float allows institutional and retail healthcare investors to take direct exposure to the DM199 stroke-trial outcome without private-venture lockups.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: